Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder

被引：83

作者：

Goddard, Andrew W. ^{[1
]}

Shekhar, Anantha ^{[1
]}

Whiteman, Aaron F. ^{[2
]}

McDougle, Christopher J. ^{[1
]}

机构：

[1] Indiana Univ, Sch Med, Dept Psychiat, Univ Hosp,UH3124, Indianapolis, IN 46202 USA

[2] Fairbanks Hosp, Clearvista Recovery Associates, Indianapolis, IN 46256 USA

来源：

DRUG DISCOVERY TODAY | 2008年 / 13卷 / 7-8期

关键词：

D O I：

10.1016/j.drudis.2007.12.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.

引用

页码：325 / 332

页数：8

共 93 条

[61]

MCDOUGLE CJ, 1994, ARCH GEN PSYCHIAT, V51, P302

[62] Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder [J].

Meira-Lima, I ;

Shavitt, RG ;

Miguita, K ;

Ikenaga, E ;

Miguel, EC ;

Vallada, H .

GENES BRAIN AND BEHAVIOR, 2004, 3 (02) :75-79

[63] Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder [J].

Moreno, Francisco A. ;

Wiegand, Christopher B. ;

Taitano, E. Keolani ;

Delgado, Pedro L. .

JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (11) :1735-1740

[64] Is the 5-HT1Dβ receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? [J].

Mundo, E ;

Richter, MA ;

Sam, F ;

Macciardi, F ;

Kennedy, JL .

AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (07) :1160-1161

[65] 5HT1Dβ Receptor gene implicated in the pathogenesis of Obsessive-Compulsive Disorder:: further evidence from a family-based association study [J].

Mundo, E ;

Richter, MA ;

Zai, G ;

Sam, F ;

McBride, J ;

Macciardi, F ;

Kennedy, JL .

MOLECULAR PSYCHIATRY, 2002, 7 (07) :805-809

[66] The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants [J].

Nakamura, M ;

Ueno, S ;

Sano, A ;

Tanabe, H .

MOLECULAR PSYCHIATRY, 2000, 5 (01) :32-38

[67] High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind tyial [J].

Ninan, PT ;

Koran, LM ;

Kiev, A ;

Davidson, JRT ;

Rasmussen, SA ;

Zajecka, JM ;

Robinson, DG ;

Crits-Christoph, P ;

Mandel, FS ;

Austin, C .

JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (01) :15-22

[68] Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression [J].

Otsuka, Tatsui ;

Togo, Takashi ;

Sugiyama, Naoya ;

Uehara, Kumi ;

Yoshimi, Asuka ;

Karashima, Aya ;

Shioya, Hiromi ;

Hirayasu, Yoshio .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (02) :564-566

[69] Citalopram intravenous infusion in resistant obsessive-compulsive disorder: An open trial [J].

Pallanti, S ;

Quercioli, L ;

Koran, LM .

JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) :796-801

[70] Memantine augmentation for refractory obsessive-compulsive disorder [J].

Pasquini, Massimo ;

Biondi, Massimo .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (06) :1173-1175

← 1 2 3 4 5 6 7 8 9 10 →